
Why your workplace wellness program isn't reducing stress—and how to fix it
And yet burnout is worse than ever.
Post-pandemic, 77% of U.S. employees report experiencing workplace stress, according to the American Psychological Association, and 82% say they're at risk of burnout. Experts blame collaboration overload, digital fatigue, and blurred work-life boundaries. Even artificial intelligence tools like ChatGPT, intended to streamline work, can amplify pressure by raising expectations for speed and output.
This disconnect exposes a hard truth: More wellness spending doesn't mean better employee well-being. If anything, it masks the root of the problem.
The Corporate Wellness Paradox
The more companies invest in wellness, the worse employees seem to feel. Is wellness spending the cause of burnout? Probably not. But it's clearly not preventing it either. So why are both rising in tandem?
1. Wellness as a deflection, not a solution. The 10 most dangerous words in business: Burnout is an organizational problem that needs an organizational solution.
Too often, companies outsource that responsibility—handing out mindfulness apps rather than asking why employees need them in the first place. Like blaming the canary instead of clearing the toxic mine, we focus on individual resilience instead of fixing the system.
2. Perks that miss the point. Wellness perks like yoga sessions sound good, but they don't address what's actually broken: unsustainable workloads, poor management, lack of autonomy, and toxic cultures. These programs treat symptoms, not causes. It's like handing out umbrellas in a flood and calling it disaster relief.
3. Branding over behavior. Wellness is often treated as a recruitment asset —front and center in job postings and Mental Health Awareness Month campaigns, but rarely integrated into how work actually gets done. If wellness isn't embedded in deadlines, resourcing, and manager training, it won't move the needle. The result? While 81% of employers say their well-being programs are effective, 61% of employees disagree. That gap signals a deeper issue: performative wellness that looks good on paper but fails in practice.
4. The illusion of progress. Companies often equate the presence of wellness programs with progress. But few measure what matters: burnout rates, psychological safety, and team performance. When wellness becomes symbolic, it can obscure the deeper structural problems driving stress.
How Companies Can Improve Their Workplace Wellness Programs
If traditional wellness programs aren't solving the problem, what will?
Start by shifting from symbolic gestures to structural change. The most effective strategies don't focus on fixing individuals—they fix the systems creating burnout in the first place. Here are five ways to start.
1. Measure what matters. Don't confuse participation with impact. It's one thing to track completion rates; it's another to measure real behavioral outcomes. Metrics like absenteeism, turnover, psychological safety, and employee net promoter scores offer a far clearer picture of employee well-being than satisfaction surveys ever could.
2. Ask better, validated questions. Move beyond generic surveys. Use research-backed questions from sources like Mental Health America, having employees rate statements such as:
My work stress affects my mental health.
My manager provides emotional support to help me manage my stress.
These surveys reveal insights about workload, leadership, and organizational culture—three of the strongest predictors of workplace mental health.
3. Rethink ROI. The best wellness investments aren't flashy—they're foundational. Fair compensation, job security, schedule flexibility, and a culture of respect aren't perks; they're prerequisites for a healthy, high-performing workplace—and exactly what workers want. These elements do more to buffer against chronic stress than any app or wellness challenge ever could.
4. Train managers as mental health allies. People don't leave jobs—they leave bad bosses. Train leaders to recognize burnout, normalize open conversations, and model healthy boundaries. Research shows managers influence employee mental health more than therapists. That's a leadership skill companies can't afford to ignore.
5. Design work differently. Instead of pushing employees to 'build resilience,' ask how your organization might reduce the need for it. Redesign roles, expectations, and collaboration norms to create environments in which people don't have to constantly recover from their jobs.
We Don't Need More Wellness Programs—We Need Better Workplaces
If companies frame wellness as a benefit instead of a responsibility, they'll keep spending billions while burnout grows.
The real opportunity isn't in launching the next app or hosting another webinar. It's in rethinking how we design work itself.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 3 Healthcare Stocks Paying the Highest Dividends of 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
20 minutes ago
- Bloomberg
How to Stay Safe as Smoky Air Blankets US
Hi! It's Madison in New York. If you've found it harder to breathe recently, you're not alone. But first... A couple months ago, I noticed that I was coughing a lot on my weekly runs. I've been running for years and I'm currently training for my third marathon, so it wasn't the result of simply being out-of-shape. Before long, I realized my cough was much worse on days when the air quality in New York was particularly bad. Recently, that's felt like more and more often.
Yahoo
an hour ago
- Yahoo
FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial
The US Food and Drug Administration (FDA) has conditionally approved TransMedics Group's investigational device exemption (IDE) to commence the next-generation OCS ENHANCE Heart study. Part A of the trial will focus on supporting prolonged heart perfusion leveraging the OCS Heart System. OCS Heart comprises a portable, warm perfusion system, which is said to maintain a donor heart in a metabolically active state, allowing physicians to monitor and assess the heart's condition and viability. Part B aims to demonstrate the OCS Heart perfusion's superiority in donation after brain death (DBD) cases over traditional static cold storage methods. This part is aimed at supporting the potential expansion of the system use for DBD hearts, which are currently ineligible for OCS perfusion and preservation. The anticipated sample size for both parts of the trial is set to exceed 650 subjects, which the company believes would make the largest heart preservation for transplant trial ever worldwide. TransMedics Group CEO and president Waleed Hassanein said: "The recent FDA approvals to initiate our Next-Gen OCS ENHANCE Heart and DENOVO Lung trials mark key milestones in our ongoing commitment to transforming the standard of care and addressing the major clinical needs of the cardiothoracic transplant community. "We are thrilled to be in a position to initiate both trials in the fourth quarter of 2025 while we continue to work collaboratively with the FDA to address any remaining questions related to pre-clinical testing. 'As I have stated before, we hope these two trials will be major catalysts for clinical adoption for both heart and lung throughout 2026 and beyond." In 2023, the company completed the acquisition of a premier US charter flight operator, Summit Aviation. This move has established TransMedics Aviation as the first dedicated national air logistics provider exclusively for organ transplantation in the US. "FDA grants conditional approval for TransMedics' OCS ENHANCE Heart trial" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Connectez-vous pour accéder à votre portefeuille